Chromosomes are blocks of DNA (deoxyribonucleic acid). They contain very detailed and specific instructions that determine: How the cells in a baby's body develop. What features the baby will have, ...

Observed on April 17, World Hemophilia Day aims to spread awareness regarding the challenges faced by those living with bleeding disorders. The focus is on timely care and access to treatment, which ...

Hemophilia is a rare and often misunderstood disease. Many people only know that it’s a blood disorder, and after that, myths and misinformation abound. So what exactly is hemophilia? Alisa Wolberg, ...

Because children with hemophilia lack blood clotting factor proteins, they can be more likely to experience prolonged, heavy bleeding. In cases of severe hemophilia, bleeding may be spontaneous and ...

Many people with hemophilia A can lead ordinary, active lives. Learning more about this genetic condition can support effective long-term management strategies. Hemophilia A is a genetic condition ...

Queen's University researcher Paula James has revealed women who are carriers of hemophilia A, an inherited bleeding disorder, experience abnormal bleeding in about 30 per cent of cases. Dr. James is ...

Hemophilia is an inherited bleeding disorder. This means it’s passed down in genes. People who carry the genetic information but do not have the disorder can still pass the gene to their children.

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by low levels of the blood protein called factor 9. Factor 9 is a specialized protein necessary for blood ...

The primary symptoms of hemophilia A are excessive bleeding and easy bruising. Excessive bleeding may occur after major trauma in people with hemophilia A, but it can also occur after more minor ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?